Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Inclusion Criteria

• •Histologically or cytologically confirmed local advanced or metastatic stage IIIB/IV NSCLC.
• •Have been treated with gefitinib and achieved completed response, partial remission, or stable disease within 3 months after first dose of gefitinib.
• •At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors.
• •Signed and dated informed consent before the start of specific protocol procedures.